ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 258 filers reported holding ACCELERON PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $79,548,000 | +13.8% | 462,239 | -17.0% | 0.54% | +13.2% |
| Q2 2021 | $69,905,000 | +2.1% | 557,055 | +0.0% | 0.48% | -16.1% |
| Q1 2021 | $68,445,000 | -3.9% | 556,934 | -0.0% | 0.57% | +1.1% |
| Q4 2020 | $71,257,000 | +25.3% | 556,935 | +10.2% | 0.56% | +5.6% |
| Q3 2020 | $56,868,000 | +56.7% | 505,380 | +32.6% | 0.53% | +39.4% |
| Q2 2020 | $36,300,000 | +45.1% | 381,009 | -21.0% | 0.38% | +38.3% |
| Q1 2020 | $25,012,000 | -2.2% | 482,558 | +0.0% | 0.28% | +1.1% |
| Q4 2019 | $25,584,000 | +17.4% | 482,530 | -12.5% | 0.27% | -5.2% |
| Q3 2019 | $21,790,000 | +39.5% | 551,500 | +44.4% | 0.29% | +48.2% |
| Q2 2019 | $15,622,000 | +39.5% | 381,948 | +58.8% | 0.20% | +36.4% |
| Q1 2019 | $11,201,000 | +5.9% | 240,500 | -0.9% | 0.14% | -11.7% |
| Q4 2018 | $10,572,000 | +47.8% | 242,758 | +94.2% | 0.16% | +70.5% |
| Q3 2018 | $7,154,000 | +52.0% | 125,000 | +28.9% | 0.10% | +28.4% |
| Q2 2018 | $4,707,000 | +100.6% | 97,000 | +61.7% | 0.07% | +85.0% |
| Q1 2018 | $2,346,000 | -24.3% | 60,000 | -17.8% | 0.04% | -25.9% |
| Q4 2017 | $3,098,000 | -29.7% | 73,000 | -38.1% | 0.05% | -29.9% |
| Q3 2017 | $4,404,000 | +34.2% | 118,000 | +9.3% | 0.08% | +24.2% |
| Q2 2017 | $3,282,000 | -31.9% | 108,000 | -40.7% | 0.06% | -33.3% |
| Q1 2017 | $4,818,000 | +25.0% | 182,000 | +20.5% | 0.09% | +5.7% |
| Q4 2016 | $3,853,000 | +13.3% | 151,000 | +60.6% | 0.09% | +7.3% |
| Q3 2016 | $3,402,000 | +25.1% | 94,000 | +17.5% | 0.08% | +15.5% |
| Q2 2016 | $2,719,000 | -9.9% | 80,000 | -30.4% | 0.07% | -5.3% |
| Q1 2016 | $3,018,000 | -48.4% | 115,000 | -4.2% | 0.08% | -52.2% |
| Q4 2015 | $5,851,000 | +133.1% | 120,000 | +19.0% | 0.16% | +153.2% |
| Q3 2015 | $2,510,000 | -20.7% | 100,800 | +0.8% | 0.06% | -6.1% |
| Q2 2015 | $3,164,000 | +22.2% | 100,000 | +47.1% | 0.07% | +26.9% |
| Q1 2015 | $2,589,000 | +20.8% | 68,000 | +23.6% | 0.05% | +15.6% |
| Q4 2014 | $2,143,000 | – | 55,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |